Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Report Overview
In 2023, the highest incident cases of Glioblastoma Multiforme (GBM) were from China and India. Glioblastoma Multiforme is a fast-growing and aggressive brain tumor. It is also referred to as a grade IV astrocytoma. GBM invades the nearby brain tissue but generally does not spread to distant organs.
There are only a handful of innovator treatment options approved for the treatment of GBM and most conventional marketed drugs are small molecules, which are administered orally. However, the majority of pipeline drugs for the treatment of GBM are biologics
| Key Mechanism of Action (Marketed) | · Genes, Nucleic Acids, and Related Components Inhibitors
· Biological Factor Inhibitor · Enzyme Inhibitor · Receptor Agonist |
| Key Routes of Administration (Marketed) | · Oral
· Topical · Injection |
| Key Molecule Type (Marketed) | · Small Molecule
· Biologic |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Glioblastoma Multiforme Marketed and Pipeline Drugs Market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Glioblastoma Multiforme.
The report also provides actionable insights on the clinical and commercial landscapes of Glioblastoma Multiforme drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
| Key Mechanisms of Action (Pipeline) | · Enzyme Inhibitor
· Cytotoxic to Cell · Protein and Peptide Inhibitor · Receptor Antagonist · Receptor Inhibitor · Biological Factor Inhibitor |
| Key Routes of Administration (Pipeline) | · Injection
· Oral · Topical · Suppository · Inhalational |
| Key Molecule Types (Pipeline) | · Biologics
· Small Molecules · Oligonucleotide |
| Top Sponsors (Marketed and Pipeline Drugs) | · National Cancer Institute, the US
· Novartis AG · Duke University · Mayo Clinic · Celgene Corp |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Glioblastoma Multiforme Marketed Drugs Segmentation by Mechanisms of Action
The key MoA in the marketed drugs for Glioblastoma Multiforme are genes, nucleic acids and related components inhibitors, biological factor inhibitor, enzyme inhibitor, and receptor agonist. The majority of marketed drugs used for GBM were genes, nucleic acids and related components inhibitors in 2023, followed by transporter inhibitor.
Glioblastoma Multiforme Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of men Glioblastoma Multiforme Marketed Drugs
Glioblastoma Multiforme Marketed Drugs Segmentation by Routes of Administration
Most of the Glioblastoma Multiforme marketed drugs are orally administered. It is followed by injection and topical.
Glioblastoma Multiforme Marketed Drugs Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of Glioblastoma Multiforme Marketed Drugs
Glioblastoma Multiforme Marketed Drugs Segmentation by Molecule Types
The key molecule types in the marketed drugs for Glioblastoma Multiforme are small molecule and biologic. The majority of marketed drugs for GBM were small molecules in 2023.
Glioblastoma Multiforme Marketed Drugs Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Glioblastoma Multiforme Marketed Drugs
Glioblastoma Multiforme Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA in the Pipeline drugs for Glioblastoma Multiforme are enzyme inhibitor, cytotoxic to cell, protein and peptide inhibitor, receptor antagonist, receptor inhibitor, and biological factor inhibitor. In 2023, enzyme inhibitor was the leading MoA for Glioblastoma Multiforme pipeline drugs.
Glioblastoma Multiforme Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of Glioblastoma Multiforme Pipeline Drugs
Glioblastoma Multiforme Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration for GBM are injection, suppository, topical, inhalational, and oral. The majority of pipeline drugs for GBM were injection therapies, followed by oral drugs in 2023.
Glioblastoma Multiforme Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of Glioblastoma Multiforme Pipeline Drugs
Glioblastoma Multiforme Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Glioblastoma Multiforme pipeline drugs market are biologics, small molecules, and oligonucleotide. In 2023, the pipeline of drugs for GBM was dominated by biologic molecules type.
Glioblastoma Multiforme Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Glioblastoma Multiforme Pipeline Drugs
Glioblastoma Multiforme Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in the Glioblastoma Multiforme marketed and pipeline drugs market are the National Cancer Institute, the US, Novartis AG, Duke University, Mayo Clinic, and Celgene Corp. In 2023, the National Cancer Institute, the US conducted the highest number of completed trials, followed by Novartis AG
Glioblastoma Multiforme marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy the Full Report for More Sponsor Insights into the Glioblastoma Multiforme Marketed and Pipeline Drugs Market
Segments Covered in the Report
Glioblastoma Multiforme Marketed Drugs Mechanism of Action (Number of Drugs, 2023)
- Genes, Nucleic Acids, and Related Components Inhibitors
- Biological Factor Inhibitor
- Enzyme Inhibitor
- Receptor Agonist
Glioblastoma Multiforme Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Topical
Glioblastoma Multiforme Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Enzyme Inhibitor
- Cytotoxic to Cell
- Protein and Peptide Inhibitor
- Receptor Antagonist
- Receptor Inhibitor
- Biological Factor Inhibitor
Glioblastoma Multiforme Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Topical
- Suppository
- Inhalational
Glioblastoma Multiforme Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologics
- Small Molecules
- Oligonucleotide
Scope
GlobalData’s GBM: The competitive Landscape in the report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. The other core components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies by reviewing pipeline products and technologies and identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Glioblastoma Multiforme market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glioblastoma Multiforme market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which was the leading MoA for Glioblastoma Multiforme marketed drugs in 2023?
The majority of marketed drugs used for GBM were genes, nucleic acids and related components inhibitors in 2023.
-
Which was the leading RoA for Glioblastoma Multiforme marketed drugs in 2023?
In 2023, most of the marketed drugs for Glioblastoma Multiforme were administered orally.
-
Which was the leading MoA for Glioblastoma Multiforme pipeline drugs in 2023?
In 2023, enzyme inhibitor was the leading MoA for Glioblastoma Multiforme pipeline drugs.
-
Which was the leading RoA for Glioblastoma Multiforme pipeline drugs in 2023?
Most pipeline drugs for Glioblastoma Multiforme were injectable in 2023.
-
Which was the leading molecule type for Glioblastoma Multiforme pipeline drugs in 2023?
In 2023, the pipeline of drugs for GBM was dominated by biologic molecule type.
-
Who are the top sponsors for the Glioblastoma Multiforme marketed and pipeline drugs market?
A few of the top sponsors in the Glioblastoma Multiforme marketed and pipeline drugs market are the National Cancer Institute, the US, Novartis AG, Duke University, Mayo Clinic, and Celgene Corp.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Glioblastoma Multiforme (GBM) reports